Bortezomib-induced Apoptosis in the Treatment of Non-small Cell Lung Cancer

Lung cancer, which can be classified into nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is the leading cause of cancerrelated death in the world. NSCLC, which accounts for 80 to 85% of all lung cancers, is distinguished from SCLC by its clinical course and its response to chemotherapy and radiotherapy. More than 70% of NSCLC patients present with unresectable locally advanced or metastatic disease, so chemotherapy with or without radiotherapy remains the mainstay of lung cancer treatment. Despite advances in the past few decades, current chemotherapy regimens have only limited efficacy with modest survival benefit and significant toxicity in NSCLC patients. Novel therapies, especially those targeting cell Abstract